Markets:

Overview

News

Currencies

International

Treasuries

Nanobiotix S.A. - ADSs (NQ:NBTX)

34.20 -1.06 (-3.01%)

Streaming Delayed Price Updated: 2:38 PM EDT, Sep 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Nanobiotix S.A. - ADSs

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Earnings Scheduled For September 8, 2021 ↗

September 08, 2021

Companies Reporting Before The Bell • Nanobiotix (NASDAQ:NBTX) is likely to report earnings for its first quarter. • Waterdrop (NYSE:WDH) is expected to report...

Via Benzinga

Nanobiotix to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 07, 2021

From NANOBIOTIX

Via Business Wire

Earnings Scheduled For September 3, 2021 ↗

September 03, 2021

Companies Reporting After The Bell • IRSA Propiedades (NASDAQ:IRCP) is projected to report earnings for its fourth quarter. • Nanobiotix (NASDAQ:NBTX) is...

Via Benzinga

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline ↗

August 18, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Nanobiotix Provides Second Quarter Operational and Financial Update

July 20, 2021

From NANOBIOTIX

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

July 14, 2021

Gainers AcelRx Pharmaceuticals (NASDAQ:ACRX

Via Benzinga

Nanobiotix Starts New NBTXR3 Study In Lung Cancer Patients ↗

July 01, 2021

Nanobiotix (NASDAQ: NBTX) initiated a new Phase 1 study evaluating NBTXR3 activated by radiation therapy (RT) for patients with non-small cell lung cancer (NSCLC)...

Via Benzinga

NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer

June 30, 2021

From NANOBIOTIX

Via Business Wire

NANOBIOTIX to Host Virtual KOL Event Discussing Potential First-in-Class Radioenhancer NBTXR3 In Immunotherapy on June 11, 2021

June 07, 2021

From NANOBIOTIX

Via Business Wire

The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact ↗

June 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 3) BioCryst Pharmaceuticals,...

Via Benzinga

Nanobiotix's Nanoparticle Technology Shows Tumor-Killing Effect in Early-Stage Head & Neck Cancer ↗

June 04, 2021

Nanobiotix (NASDAQ: NBTX), ahead of the 2021 Annual Meeting of the American Society for Clinical Oncology meeting, has said that its nanoparticles were able to shrink...

Via Benzinga

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure

June 03, 2021

From NANOBIOTIX

Via Business Wire

The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements ↗

June 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) Anika Therapeutics, Inc. (...

Via Benzinga

NANOBIOTIX Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive Board to Support Global Expansion

June 01, 2021

From NANOBIOTIX

Via Business Wire

NANOBIOTIX to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

May 26, 2021

From NANOBIOTIX

Via Business Wire

Nanobiotix Announces the Appointment of Dr. Gary Phillips as Chairman of the Nanobiotix Supervisory Board

May 25, 2021

From Nanobiotix

Via Business Wire

CORRECTING and REPLACING Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology

May 21, 2021

From Nanobiotix

Via Business Wire

Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology

May 19, 2021

From Nanobiotix

Via Business Wire

Nanobiotix to Present at the UBS Global Healthcare Virtual Conference

May 12, 2021

From Nanobiotix

Via Business Wire

Nanobiotix, LianBio Ink NBTXR3 Development Pact In Asia For Solid Tumor Settings ↗

May 12, 2021

Nanobiotix (NASDAQ: NBTX) has announced a partnership with LianBio to develop and commercialize Nanobiotix's lead product candidate NBTXR3, in...

Via Benzinga

NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets

May 11, 2021

From NANOBIOTIX

Via Business Wire

NANOBIOTIX Announces First Quarter Operational and Financial Updates

April 29, 2021

From NANOBIOTIX

Via Business Wire

NANOBIOTIX to Present Four Posters Including Updates From Priority Head and Neck Cancer and Immunotherapy Development Pathways at the 2021 Annual Meeting of the American Society for Clinical Oncology

April 28, 2021

From NANOBIOTIX

Via Business Wire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

April 16, 2021

Gainers BioCryst Pharmaceuticals (NASDAQ:BCRX) shares rose 11.13% to $11.32 during Friday's regular session. As of 08:06 EST, this security is trading at a volume of 8...

Via Benzinga

Nanobiotix Combined Shareholders Meeting to Be Held April 28, 2021

April 12, 2021

From Nanobiotix

Via Business Wire

The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx ↗

April 24, 2021

Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:...

Via Benzinga

NANOBIOTIX Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F

April 07, 2021

From NANOBIOTIX

Via Business Wire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.